All Posts Tagged With: "WCRX"
(MYL) Mylan Earns FDA Approval
Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb’s (BMY) drug Reyataz and...
5Dec2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Analyst Maintains Outperform on Shares
We continue to have an Outperform recommendation on Watson Pharmaceuticals, Inc. (WPI), with a target price of $79.00, following the release of second quarter 2011 results. Watson Pharma’s second quarter earnings of $1.01 per share (excluding special items) outpaced the Zacks...
26Aug2011 | vitalstocks | 0 comments | Continued(WCRX) Warner Chilcott Announces Change in Leadership of Research & Development Division
Warner Chilcott (WCRX) recently announced that there will be a change at the helm of its research & development (R&D) division from the beginning of next year. The need for change arose following the decision of Warner Chilcott’s incumbent R&D chief, Dr. Fawzi,...
1Jul2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals and Columbia Laboratories Drug’s NDA Accepted
Watson Pharmaceuticals Inc. (WPI) along with Columbia Laboratories Inc. (CBRX) recently announced that the latter’s New Drug Application (NDA) for Prochieve (progesterone gel) has been accepted by the US Food and Drug Administration (FDA). The companies are looking to get Prochieve...
29Jun2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We recently reaffirmed our Neutral stance on Watson Pharmaceuticals Inc. (WPI) following the release of fourth quarter and fiscal year 2010 financial results. Quarterly earnings of 93 cents per share were in line with the Zacks Consensus Estimate and 8 cents above the year-ago...
17Mar2011 | vitalstocks | 0 comments | Continued(WCRX) Warner Chilcott Earns US Food and Drug Administration Approval for Actonel
Warner Chilcott plc (WCRX) recently announced that the US Food and Drug Administration (FDA) approved a next-generation version of its postmenopausal osteoporosis treatment Actonel. The company plans to market this drug as Atelvia in the US and launch it commercially early next...
12Oct2010 | vitalstocks | 0 comments | Continued(WCRX) Warner Chilcott – Revenues Nearly Triple
Warner Chilcott plc (WCRX) profits are up sharply after a recent acquisition. Analysts are projecting nice growth and the stock is still trading at a nice value. Company Description Warner Chilcott makes pharmaceuticals for gastroenterology, women’s healthcare, dermatology...
18Mar2010 | vitalstocks | 0 comments | Continued(PG) The Procter & Gamble Company Acquires Ambi Pur Brand From Sara Lee Corporation
The Procter & Gamble Company (PG) signed an agreement to acquire the Ambi Pur Brand from Sara Lee Corporation (SLE) for €320 million ($470 million). Ambi Pur is a leading global air care brand with several toilet care products. The company has strong a presence in Western...
17Dec2009 | vitalstocks | 0 comments | Continued(WCRX) Warner Chilcott Limited – boosted earnings guidance following the excellent quarterly results
Warner Chilcott Limited (WCRX) is raising guidance, amid economic turmoil, based an excellent quarterly results. Analysts are raising their forecasts and the stock was just added to a major index. Company Description Warner Chilcott is a leading specialty pharmaceutical company...
23Dec2008 | Shawn | Comments Off | Continued